Alpine Immune Sciences Initiates Trial Collaboration With Merck
Alpine Immune Sciences Inc (NASDAQ:ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK). This collaboration…
Alpine Immune Sciences To Collaborate With Merck On Immuno-Oncology Study To Evaluate ALPN-202 In Combination With KEYTRUDA (pembrolizumab)
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a clinical trial
Moderna’s COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ:MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine.…
Merck’s Keytruda-Chemo Combo Wins European Approval In Esophagus Cancer
The European Commission has approved Merck & Co Inc’s (NYSE:MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment…
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Citius Shows a Promising Future as Share Prices Keep Going up
In a world facing a global pandemic, advancements in the healthcare sector are pivotal, especially with unmet medical needs of different ranges of diseases and at different levels.
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival In Patients With Persistent, Recurrent Or Metastatic Cervical Cancer
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based
AstraZeneca Announced Koselugo Approved in the EU for Children with NF1
AstraZeneca (NYSE: AZN) and MSD's (NYSE: MRK) Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (